Intervention Review

Tegaserod for the treatment of irritable bowel syndrome and chronic constipation

  1. Beti W Evans1,*,
  2. Wendy K Clark2,
  3. David J Moore3,
  4. Peter J Whorwell4

Editorial Group: Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Group

Published Online: 17 OCT 2007

Assessed as up-to-date: 30 JUL 2007

DOI: 10.1002/14651858.CD003960.pub3


How to Cite

Evans BW, Clark WK, Moore DJ, Whorwell PJ. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. Cochrane Database of Systematic Reviews 2007, Issue 4. Art. No.: CD003960. DOI: 10.1002/14651858.CD003960.pub3.

Author Information

  1. 1

    University of Hertfordshire, School of Pharmacy, Hatfield, UK

  2. 2

    Keele University, Medicines Management, Newcastle-under-Lyme, Staffordshire, UK

  3. 3

    University of Birmingham, Aggressive Research Intelligence Facility, University of Birmingham, West Midlands, UK

  4. 4

    Wythenshawe Hospital, Medical Academic Department, Manchester, UK

*Beti W Evans, School of Pharmacy, University of Hertfordshire, College Lane Campus, Hatfield, AL10 9AB, UK. b.w.evans@herts.ac.uk.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 17 OCT 2007

SEARCH

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Yeong Yeh Lee, What’s New in the Toolbox for Constipation and Fecal Incontinence?, Frontiers in Medicine, 2014, 1,

    CrossRef

  2. 2
    Sharon L. Stein, Chronic Pelvic Pain, Gastroenterology Clinics of North America, 2013, 42, 4, 785

    CrossRef

  3. 3
    Hans Törnblom, Greger Lindberg, A 21st Century Look at the Spectrum of Gastrointestinal Motility Disorders. What is Dysmotility; What is Functional?, Gastroenterology Clinics of North America, 2011, 40, 4, 715

    CrossRef

  4. 4
    F. Cremonini, G. Chiarioni, A. Lembo, Evolving concepts in chronic constipation in Europe and elsewhere: not worlds apart, Neurogastroenterology & Motility, 2011, 23, 8
  5. 5
    N.M. Thoua, C.D. Murray, Irritable bowel syndrome, Medicine, 2011, 39, 4, 214

    CrossRef

  6. 6
    Michael Camilleri, Emeran A. Mayer, Reply, Gastroenterology, 2010, 138, 2, 791

    CrossRef

  7. 7
    Evelin Painsipp, Anaid Shahbazian, Peter Holzer, Alosetron, cilansetron and tegaserod modify mesenteric but not colonic blood flow in rats, British Journal of Pharmacology, 2009, 158, 5
  8. 8
    Michael Camilleri, Emeran A. Mayer, Developing Irritable Bowel Syndrome Guidelines Through Meta-analyses: Does the Emperor Really Have New Clothes?, Gastroenterology, 2009, 137, 3, 766

    CrossRef

  9. 9
    Spencer D. Dorn, Joel F. Farley, Richard A. Hansen, Nilay D. Shah, Robert S. Sandler, Direct-to-Consumer and Physician Promotion of Tegaserod Correlated With Physician Visits, Diagnoses, and Prescriptions, Gastroenterology, 2009, 137, 2, 518

    CrossRef

  10. 10
    Toru Hiyama, Masaharu Yoshihara, Shinji Tanaka, Ken Haruma, Kazuaki Chayama, Effectiveness of prokinetic agents against diseases external to the gastrointestinal tract, Journal of Gastroenterology and Hepatology, 2009, 24, 4
  11. 11
    Jan Tack, Stefan Müller–Lissner, Treatment of Chronic Constipation: Current Pharmacologic Approaches and Future Directions, Clinical Gastroenterology and Hepatology, 2009, 7, 5, 502

    CrossRef

  12. 12
    Jian Ping Liu, Min Yang, Yunxia Liu, Mao Ling Wei, Sameline Grimsgaard, Herbal medicines for treatment of irritable bowel syndrome, The Cochrane Library,
  13. 13
    Alexander C Ford, Paul Moayyedi, Nicholas J Talley, Irritable Bowel Syndrome,
  14. 14
    Ruey Terng Ng, Nai Ming Lai, Way Seah Lee, Hak Lee Ang, Kai Ming Teo, Transcutaneous electrical nerve stimulation (TENS) for treatment of constipation in children, The Cochrane Library,